GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: Two prospective randomized controlled multi-centre studies in IVF patients

Human Reproduction

Volumn 28, Issue 9, 2013, Pages 2511-2521

  Humaidan, P ^a,b   Polyzos, N P ^c   Alsbjerg, B ^a   Erb, K ^d   Mikkelsen, A L ^e   Elbaek, H O ^f   Papanikolaou, E G ^g   Andersen, C Y ^h  

^a SKIVE REGIONAL HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c CENTRE FOR REPRODUCTIVE MEDICINE   (Belgium)

^d ODENSE UNIVERSITY HOSPITAL   (Denmark)

^e HOLBÆK HOSPITAL   (Denmark)

^f HORSENS REGIONAL HOSPITAL   (Denmark)

^g ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^h Mental Health Services CPH   (Denmark)

Author keywords

GnRH agonist trigger; GnRH antagonist; hCG; IVF; ovarian hyperstimulation syndrome

Indexed keywords

BUSERELIN; CHORIONIC GONADOTROPIN; ESTRADIOL; ESTROFEM; FOLLITROPIN; GANIRELIX; LUTEINIZING HORMONE; PROGESTERONE; RECOMBINANT FOLLITROPIN;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLITROPIN BLOOD LEVEL; HORMONAL THERAPY; HUMAN; LUTEAL PHASE; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OOCYTE RETRIEVAL; OUTCOME ASSESSMENT; OVARY HYPERSTIMULATION; OVULATION; PREGNANCY OUTCOME; PROGESTERONE BLOOD LEVEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

GNRH AGONIST TRIGGER; GNRH ANTAGONIST; HCG; IVF; OVARIAN HYPERSTIMULATION SYNDROME;

ADULT; CHORIONIC GONADOTROPIN; CORPUS LUTEUM; DENMARK; DOSE-RESPONSE RELATIONSHIP, DRUG; EARLY TERMINATION OF CLINICAL TRIALS; FEASIBILITY STUDIES; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE, HUMAN; GONADOTROPIN-RELEASING HORMONE; HUMANS; INCIDENCE; INDIVIDUALIZED MEDICINE; INFERTILITY, FEMALE; OVARIAN HYPERSTIMULATION SYNDROME; OVARY; OVULATION INDUCTION; RECOMBINANT PROTEINS; RISK; SEVERITY OF ILLNESS INDEX;

EID: 84883137526     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/det249     Document Type: Article

References (44)

1. Andersen CY, Humaidan P, Ejdrup HB, Bungum L, Grondahl ML, Westergaard LG. Hormonal characteristics of follicular fluid from women receiving either GnRH agonist or hCG for ovulation induction. Hum Reprod 2006;21:2126-2130. (Pubitemid 44303920)
2. Babayof R, Margalioth EJ, Huleihel M, Amash A, Zylber-Haran E, Gal M, Brooks B, Mimoni T, Eldar-Geva T. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: A prospective randomized trial. Hum Reprod 2006; 21:1260-1265.
3. Beckers NG, Macklon NS, Eijkemans MJ, Ludwig M, Felberbaum RE, Diedrich K, Bustion S, Loumaye E, Fauser BC. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment. J Clin Endocrinol Metab 2003;88:4186-4192. (Pubitemid 37158033)
4. Benadiva C, Engmann L. Intensive luteal phase support after GnRH agonist trigger: it does help. Reprod Biomed Online 2012;25:329-330.
5. Casper RF, Yen SS. Induction of luteolysis in the human with a long-acting analog of luteinizing hormone-releasing factor. Science 1979; 205:408-410. (Pubitemid 9243922)
6. Castillo JC, Dolz M, Bienvenido E, Abad L, Casan EM, Bonilla-Musoles F. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support. Reprod Biomed Online 2010;20:175-181.
7. Devroey P, Polyzos NP, Blockeel C. AnOHSS-Free Clinicbysegmentation of IVF treatment. Hum Reprod 2011;26:2593-2597.
8. Engmann L, DiLuigi A, Schmidt D, Benadiva C, Maier D, Nulsen J. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study. Fertil Steril 2008; 89:554-561. (Pubitemid 351337666)
9. Eppig JJ. FSH stimulates hyaluronic acid synthesis by oocyte-cumulus cell complexes from mouse preovulatoryfollicles. Nature 1979;281:483-484. (Pubitemid 10244270)
10. Gonen Y, Balakier H, Powell W, Casper RF. Use of gonadotropin-releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab 1990;71:918-922.
11. Griffin D, Benadiva C, Kummer N, Budinetz T, Nulsen J, Engmann L. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders. Fertil Steril 2012;97:1316-1320.
12. Haning RV Jr, Strawn EY, Nolten WE. Pathophysiology of the ovarian hyperstimulation syndrome. Obstet Gynecol 1985;66:220-224. (Pubitemid 15049726)
13. Hoff JD, Quigley ME, Yen SS. Hormonal dynamicsatmidcycle: areevaluation. J Clin Endocrinol Metab 1983;57:792-796.
14. Humaidan P. Luteal phase rescue in high-risk OHSS patients by GnRHa triggering in combination with low-dose HCG: a pilot study. Reprod Biomed Online 2009;18:630-634.
15. Humaidan P, Bredkjaer HE, Bungum L, Bungum M, Grondahl ML, Westergaard L, Andersen CY. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study. Hum Reprod 2005;20:1213-1220. (Pubitemid 40796107)
16. Humaidan P, Bungum L, Bungum M, Yding AC. Rescue of corpus luteum function with peri-ovulatory HCG supplementation in IVF/ICSI GnRH antagonist cycles in which ovulation was triggered with a GnRH agonist: a pilot study. Reprod Biomed Online 2006;13:173-178. (Pubitemid 44207763)
17. Humaidan P, Ejdrup BH, Westergaard LG, Yding AC. 1, 500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for ovulation induction: a prospective, randomized, controlled study. Fertil Steril 2010;93:847-854.
18. Humaidan P, Kol S, Papanikolaou EG. GnRH agonist for triggering of final oocyte maturation: time for a change of practice? Hum Reprod Update 2011a;17:510-524.
19. Humaidan P, Westergaard LG, Mikkelsen AL, Fukuda M, Yding AC. Levels of the epidermal growth factor-like peptide amphiregulin in follicular fluid reflect the mode of triggering ovulation: a comparison between gonadotrophin-releasing hormone agonist and urinary human chorionic gonadotrophin. Fertil Steril 2011b;95:2034-2038.
20. Humaidan P, Papanikolaou EG, Kyrou D, Alsbjerg B, Polyzos NP, Devroey P, Fatemi HM. The luteal phase after GnRH-agonist triggering of ovulation: present and future perspectives. Reprod Biomed Online 2012;24: 134-141.
21. Imbar T, Kol S, Lossos F, Bdolah Y, Hurwitz A, Haimov-Kochman R. Reproductive outcome of fresh or frozen-thawed embryo transfer is similar in high-risk patients for ovarian hyperstimulation syndrome using GnRH agonist for final oocyte maturation and intensive luteal support. Hum Reprod 2012;27:753-759.
22. Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 1991;56:213-220.
23. Kessler MJ, Reddy MS, Shah RH, Bahl OP. Structures of N-glycosidic carbohydrate units of human chorionic gonadotropin. J Biol Chem 1979; 254:7901-7908. (Pubitemid 10233617)
24. Kummer N, Benadiva C, Feinn R, Mann J, Nulsen J, Engmann L. Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist. Fertil Steril 2011;96:63-68.
25. Lainas TG, Petsas GK, Zorzovilis IZ, Iliadis GS, Lainas GT, Cazlaris HE, Kolibianakis EM. Initiation of GnRH antagonist on Day 1 of stimulation as compared to the long agonist protocol in PCOS patients. A randomized controlled trial: effect on hormonal levels and follicular development. Hum Reprod 2007;22:1540-1546. (Pubitemid 47055140)
26. Licht P, Russu V, Wildt L. On the role of human chorionic gonadotropin (hCG) in the embryo-endometrial microenvironment: implications for differentiation and implantation. Semin Reprod Med 2001;19:37-47. (Pubitemid 32489044)
27. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992; 58:249-261.
28. Orvieto R. Intensive luteal-phase support with oestradiol and progesterone after GnRH-agonist triggering: does it help? Reprod Biomed Online 2012; 24:680-681.
29. Orvieto R, Rabinson J, Meltzer S, Zohav E, Anteby E, Homburg R. Substituting HCG with GnRH agonist to trigger final follicular maturation-a retrospective comparison of three different ovarian stimulation protocols. Reprod Biomed Online 2006;13:198-201. (Pubitemid 44207766)
30. Papanikolaou EG, Pozzobon C, Kolibianakis EM, Camus M, Tournaye H, Fatemi HM, Van SA, Devroey P. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles. Fertil Steril 2006; 85:112-120. (Pubitemid 43063432)
31. Papanikolaou EG, Verpoest W, Fatemi H, Tarlatzis B, Devroey P, Tournaye H. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertil Steril 2011;95:1174-1177.
32. Radesic B, Tremellen K. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates. Hum Reprod 2011;26:3437-3442.
33. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
34. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Thomas S. Gonadotropin-releasing hormone agonist combined with a reduced dose of human chorionic gonadotropin for final oocyte maturation in fresh autologous cycles of in vitro fertilization. Fertil Steril 2008; 90:231-233. (Pubitemid 351885203)
35. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Hudson C. Comparison of 'triggers' using leuprolide acetate aloneor incombination with low-dose human chorionic gonadotropin. Fertil Steril 2011;95:2715-2717.
36. Strickland S, Beers WH. Studies on the role of plasminogen activator in ovulation. In vitro response of granulosa cells to gonadotropins, cyclic nucleotides, and prostaglandins. J Biol Chem 1976;251: 5694-5702.
37. Sugino N, Kashida S, Takiguchi S, Karube A, Kato H. Expression of vascular endothelial growth factor and its receptors in the human corpus luteum during the menstrual cycle and in early pregnancy. J Clin Endocrinol Metab 2000;85:3919-3924.
38. Tesarik J, Hazout A, Mendoza-Tesarik R, Mendoza N, Mendoza C. Beneficial effect of luteal-phase GnRH agonist administration on embryo implantation after ICSI in both GnRH agonist-and antagonist-treated ovarian stimulation cycles. Hum Reprod 2006;21:2572-2579. (Pubitemid 44548853)
39. Wang TH, Horng SG, Chang CL, Wu HM, Tsai YJ, Wang HS, Soong YK. Human chorionic gonadotropin-induced ovarian hyperstimulation syndrome is associated with up-regulation of vascular endothelial growth factor. J Clin Endocrinol Metab 2002;87:3300-3308.
40. Weissman A, Loumaye E, Shoham Z. Recovery of corpus luteum function after prolonged deprivation from gonadotrophin stimulation. Hum Reprod 1996;11:943-949. (Pubitemid 26177259)
41. Yding AC. Effect of FSH and its different isoforms on maturation of oocytes from pre-ovulatory follicles. Reprod Biomed Online 2002;5:232-239.
42. Yding AC, Westergaard LG, Figenschau Y, Bertheussen K, Forsdahl F. Endocrine composition of follicular fluid comparing human chorionic gonadotrophin to a gonadotrophin-releasing hormone agonist for ovulation induction. Hum Reprod 1993;8:840-843. (Pubitemid 23193674)
43. Yding AC, Leonardsen L, Ulloa-Aguirre A, Barrios-De-Tomasi J, Moore L, Byskov AG. FSH-induced resumption of meiosis in mouse oocytes: effect of different isoforms. Mol Hum Reprod 1999;5:726-731. (Pubitemid 29366869)
44. Zelinski-Wooten MB, Hutchison JS, Hess DL, Wolf DP, Stouffer RL. Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys. Hum Reprod 1995;10:1658-1666.